Technology & Devices

HTG Introduces the HTG EdgeSeq Mouse miRNA Whole Transcriptome Assay, a Comprehensive Panel for miRNA Expression Analysis for use in Translational Medicine and Preclinical Studies

TUCSON, Ariz., Aug. 29, 2018 (GLOBE NEWSWIRE) — HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a provider of instruments, reagents, and services for molecular profiling applications, today announced the pre-launch introduction of the new HTG EdgeSeq Mouse miRNA Whole Transcriptome Assay (WTA) with product availability for shipment expected in the fourth …

Read More »

Genprex Amends Options to License Additional Cancer Fighting Technologies from MD Anderson Cancer Center

AUSTIN, Texas & CAMBRIDGE, Mass.–(BUSINESS WIRE)–Genprex, Inc. (NASDAQ: GNPX), a clinical stage gene therapy company developing a new approach to treating cancer based upon a novel proprietary technology platform, announced today that it has entered into amendments with The University of Texas MD Anderson Cancer Center (MD Anderson) to extend the …

Read More »

Affimed and Genentech Collaborate to Develop Novel NK Cell Engager-Based Immunotherapeutics for Multiple Cancer Targets

Heidelberg, Germany, August 27, 2018 – Affimed N.V. (Nasdaq: AFMD), a clinical stage biopharmaceutical company focused on discovering and developing highly targeted cancer immunotherapies that harness the power of innate and adaptive immunity (NK and T cells), today announced that it has entered into a strategic collaboration agreement with Genentech, …

Read More »

Using Technology that Powers GPS Cancer, Scientists have Developed Fresh Insights into the Driving Mechanisms of a Rare Skin Cancer

CULVER CITY, Calif.–(BUSINESS WIRE)–New, peer-reviewed research utilizing NantOmics technology, which powers NantHealth’s (NASDAQ: NH) GPS Cancer ® is giving scientists fresh insights into the driving mechanisms behind a form of rare skin cancer as well as therapies to treat patients. Scientists from NantOmics as well as the University of California …

Read More »

FDA Approves Roche’s Cobas EGFR Mutation Test v2 as a Companion Diagnostic with Iressa

PLEASANTON, Calif., Aug. 23, 2018 /PRNewswire/ — Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced approval from the U.S. Food and Drug Administration (FDA) for the cobas® EGFR Mutation Test v2 as a companion diagnostic test (CDx) with IRESSA®. A CDx test provides information that is essential for the safe …

Read More »

Pfizer and Exact Sciences Enter Agreement to Co-Promote Colorectal Cancer Screening Test Cologuard

MADISON, Wis. and NEW YORK, Aug. 22, 2018 /PRNewswire/ — Exact Sciences Corp. (Nasdaq : EXAS ) and Pfizer Inc. (NYSE : PFE ) today announced an agreement through 2021 to co-promote Cologuard, the first and only FDA-approved non-invasive stool DNA screening test for colorectal cancer. Pfizer will join Exact …

Read More »

Agena Bioscience Collaborates with PerkinElmer to Optimize Liquid Biopsy Workflow

SAN DIEGO, Aug. 21, 2018 /PRNewswire/ — Agena Bioscience (Agena) announced today that they have entered into a collaboration with PerkinElmer, incorporating the LabChip® GX Touch™ nucleic acid analyzer for quality assessment and quantitation of DNA in the upfront workflow of Agena’s MassARRAY® system. The companies have focused on targeting …

Read More »

HitGen Enters Innovative Drug Discovery Research Collaboration with LG Chem by Applying DNA-Encoded Technology

CHENGDU, China, Aug. 17, 2018 (GLOBE NEWSWIRE) — HitGen Ltd today announced a multi-year major drug discovery research collaboration with LG Chem to identify novel small molecule leads for targets of interest. In this collaboration, HitGen will apply its advanced technology platform, based on DNA-encoded library design, synthesis, and screening …

Read More »

Merck and Healthy Interactions Launch Digital Health Platform Designed to Enhance Patient Engagement in Diabetes Management

KENILWORTH, N.J., Aug. 17, 2018 /PRNewswire/ — Healthy Interactions, a global leader in health education, in collaboration with Merck (NYSE : MRK ), known as MSD outside the United States and Canada, today announced the launch of map4health™ – a digital platform and mobile application in the U.S. that was …

Read More »

Natera and Fox Chase Cancer Center to Collaborate to Assess the Signatera Customized ctDNA Assay for Monitoring Kidney Cancer

SAN CARLOS, Calif., Aug. 15, 2018 /PRNewswire/ — Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, has partnered with Fox Chase Cancer Center, one of the leading cancer centers in the United States, to assess the company’s Signatera™ (Research-Use Only) customized circulating tumor DNA (ctDNA) assay for …

Read More »